Clinical trial NCT01877343: Developing a Non-invasive Cardiac Functional Health Status Measurement Device
Official title: Developing a Non-invasive Cardiac Functional Health Status Measurement Device to be Used in a Critical Population of Adults and Children With Heart Failure.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Heart Failure
Keywords: cardiac functional health classification
Congenital heart failure
chronic heart failure
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2013-06-13
Enrollment: 10
Sex: ALL
Minimum age (years): 7
Maximum age (years): 74
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a single-center, non-randomized study.Enrolled patients will be placed on a tilt table and a stress test will be performed in a total of 4 different positions. Their blood pressure will be measured at each position. Also, a pulse oximeter will be placed on the forehead to measure pulse rate and strength. These results will be compared to cardiac functional classifications defined by New York Heart Association (NYHA) criteria for adults and New York Pediatric Heart Failure (NYPHF) index for our pediatric age patients. The primary aim of this initiative is to assess the discriminatory value of a cardiac functional health classification based upon the degree of dependency of cardiac function on changes in cardiac preload and afterload circulatory volume.

Detailed description: Participants will be asked to review the informed consent and consent to the study prior to any study procedures. The study will consist of a single visit to the Medical Plaza at the University of Florida. During this visit, Enrolled patients will be placed on a tilt table and their position changed to a total of 4 different positions. Their blood pressure will be measured at each position. Also, a pulse oximeter will be placed on the forehead to measure pulse rate and strength. The study will take approximately 25 minutes. Data collected shall include a questionnaire for the patient, a list of the patient's co-morbidities, an echocardiogram or catheter lab data if available, and a list of the patient's current medications.

Eligibility criteria: Inclusion Criteria:

* Heart failure patient eligibility shall consist of the following:

Group 1a: 5 adult heart transplant patients

* Age ≥ 21 years old and \<74 years old
* Speaks and understands English
* Provides Informed Consent

Group 1b: 5 pediatric heart transplant patients

* Age ≥ 7 years old and \< 21 years old
* Speaks and understands English
* Provides Informed Consent

Group 2: 5 adult heart failure patients

* Age ≥ 21 years old and \<74 years old
* Speaks and understands English
* Provides Informed Consent

Group 3: 5 adult aged Fontan patients

* Age ≥ 21 years old and \<74 years old
* Speaks and understands English
* Provides Informed Consent

Group 4: 5 pediatric Fontan patients

* Age ≥ 7 years old and \< 21 years old
* Speaks and understands English
* Provides Informed Consent

Group 5: 5 pediatric patients limited to heart murmurs

* Age ≥ 7 years old and \< 21 years old
* Speaks and understands English
* Provides Informed Consent

Group 6: 5 normal adult patients

* Age ≥ 21 years old and \<74 years old
* Speaks and understands English
* Provides Informed Consent

Exclusion Criteria:

* • Unstable patients per judgment of the clinician prior to the start of the treatment

  * Patients unable to have blood pressure cuff measured on the upper arm
  * Inability to wear monitor on forehead
  * Patients will be excluded from the study if they have eaten, consume caffeinated beverages, or taken hypertensive medications within 2 hours of testing

Primary outcomes:
measure: Pulse Rate
timeFrame: Average pulse rate from baseline to 30 minutes
measure: Pulse Strength
timeFrame: Average pulse strength from baseline to 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Curt DeGroff, MD
role: PRINCIPAL_INVESTIGATOR
References: